NEW HAVEN, Conn. — Halda Therapeutics, a clinical-stage biotechnology company focused on developing a new class of cancer treatments known as RIPTAC™ (Regulated Induced Proximity Targeting Chimeras) therapeutics, has named Dr. Eyal Attar as its new Chief Medical Officer (CMO).
Dr. Attar brings over 25 years of experience in biotechnology research and development, as well as clinical trial leadership, particularly in advancing novel therapies for cancer. His appointment comes as Halda progresses its RIPTAC platform through clinical studies.
“Dr. Attar is a seasoned biotechnology industry veteran, and we are thrilled to have him join Halda at this pivotal time,” said Christian Schade, President and CEO of Halda Therapeutics. “As we advance our RIPTAC small molecule therapeutics in clinical trials, Eyal’s extensive expertise in clinical development and R&D strategy will be critical to achieving our goals.”
Halda is currently conducting a first-in-human Phase 1/2 clinical trial (NCT06800313) evaluating its lead candidate, HLD-0915, in patients with metastatic castration-resistant prostate cancer (mCRPC). The trial aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of HLD-0915, an orally administered monotherapy. Following dose escalation in Phase 1 to establish the maximum tolerated dose, the Phase 2 portion will focus on further evaluating efficacy and safety.
In his new role, Dr. Attar will lead clinical development activities for HLD-0915 and future RIPTAC programs, including a planned expansion into breast cancer and other serious diseases.
“Halda’s RIPTAC platform represents an exciting new modality in cancer treatment,” said Dr. Attar. “I look forward to collaborating with the exceptional team at Halda and our clinical partners to advance this promising approach for patients with prostate cancer and beyond.”
Prior to joining Halda, Dr. Attar served as CMO at Vor Bio, a clinical-stage cell and genome engineering company developing therapies for cancer. He also held senior roles at Aprea Therapeutics and Agios Pharmaceuticals, where he led multiple oncology programs and contributed to several successful investigational new drug (IND) applications. Before his industry career, Dr. Attar practiced as a hematologist/oncologist at Massachusetts General Hospital, specializing in leukemias and other blood-related cancers. He completed fellowship training at Dana-Farber Cancer Institute, residency at Brigham and Women’s Hospital, and earned his medical degree from the University of North Carolina School of Medicine.
